Algorae Pharmaceuticals Limited

Equities

1AI

AU0000296022

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 22:04:33 2024-07-03 EDT			5-day change	1st Jan Change
0.01 ^AUD	0.00%		-9.09%	0.00%

07-01	Algorae Pharmaceuticals Limited Announces Change of Company Secretary	CI
03-08	Algorae Pharmaceuticals Nears Launch of Drug Discovery Platform	MT

Living Cell Technologies Limited Resignation of Elizabeth McGregor as Joint Company Secretary

December 20, 2019 at 12:43 am

Living Cell Technologies (LCT) Limited announced that, following her resignation from Mertons Corporate Services Pty Ltd. (Mertons), Ms Elizabeth McGregor of Mertons has also resigned as Joint Company Secretary of LCT effective 20 December 2019. Mertons Managing Director Mr. Mark Licciardo continues to serve as Company Secretary of LCT.

Latest news about Algorae Pharmaceuticals Limited

Algorae Pharmaceuticals Limited Announces Change of Company Secretary	07-01	CI
Algorae Pharmaceuticals Nears Launch of Drug Discovery Platform	03-08	MT
Algorae Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Algorae Pharmaceuticals Considers Combination Therapy for NTCELL Trial	02-14	MT
Algorae Pharmaceuticals Limited Announces Change of Company Secretary	01-16	CI
Algorae Pharmaceuticals, HL Pharma Partner to Develop Cannabinoid Compound Storage and AI Platform	01-04	MT
Algorae Pharmaceuticals Secures Agreement with HL Pharma	12-27	MT
Algorae, Monash University Collaborate on Pre-Clinical Studies for Cardiovascular Diseases Drug; Shares Plunge 8%	11-22	MT
Algorae Joins CSIRO's Next Generation AI Graduate Program with Grant Funding Participation; Shares Jump 8%	23-10-30	MT
Algorae Pharmaceuticals Enters Partnership for Developing Drug Discovery AI Platform	23-10-25	MT
Algorae Pharmaceuticals Limited announced that it has received AUD 0.001125 million in funding	23-09-05	CI
Living Cell Technologies Collaborating With La Trobe University for Dementia Drug Candidate	23-09-01	MT
Living Cell Technologies Limited has Changed its Name to Algorae Pharmaceuticals Limited	23-09-01	CI
Living Cell Technologies Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Living Cell Technologies Files Provisional Patent Application for CBD-Combination Drug Candidate for Dementia	23-07-25	MT
Living Cell Technologies May Change Name to Algorae Pharmaceuticals; Shares Rise 6%	23-07-10	MT
Living Cell Technologies Limited Announces Management Changes	23-07-02	CI
Living Cell Technologies Appoints Chief Scientific Officer; Shares Jump 9%	23-06-08	MT
Living Cell Technologies Limited Appoints James A Mckenna as Chief Scientific Officer	23-06-08	CI
Living Cell Technologies Raises Additional Funds from Shortfall Offer	23-05-03	MT
Living Cell Technologies Limited Announces Change of Registered Office	23-04-16	CI
Living Cell Technologies Raising AU$2.5 Million to Fund Clinical Trial	23-03-02	MT
Living Cell Technologies Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Living Cell Technologies Appoints Executive Chair; Interim CEO Steps Down	23-01-05	MT
Living Cell Technologies Limited Announces Appointment of Mr. Madhukar "Madhu" Bhalla as Company Secretary to the Company	22-12-04	CI

Chart Algorae Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an Australia-based pharmaceutical development company. The Company is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinsonâs. Its drug candidates include NTCELL for Parkinsonâs disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinsonâs disease.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALGORAE PHARMACEUTICALS LIMITED	0.00%	11.23M
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	122B
REGENERON PHARMACEUTICALS, INC.	+16.60%	113B
ARGENX SE	+17.55%	26.22B
BIONTECH SE	-24.33%	19.01B
GENMAB A/S	-19.14%	15.71B
BEIGENE, LTD.	-17.95%	15.22B
WUXI APPTEC CO., LTD.	-46.81%	14.72B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.58B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.84B

Bio Therapeutic Drugs